ClinicalTrials.gg
CompletedNCT04171739Updated Jul 24, 2020

Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim

A Phase 1 interventional study of Itraconazole oral solution and Rifampicin Oral Capsule in Healthy, sponsored by F2G Biotech GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-24.

Sponsored by F2G Biotech GmbH · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, single-centre, fixed-sequence, open label, drug-drug interaction study in 2 groups of healthy subjects.

Group A: to evaluate the effects of itraconazole, a strong inhibitor of cytochrome P450 3A (CYP3A), upon the pharmacokinetics of olorofim .

Group B: t o evaluate the effects rifampicin, a strong inducer of CYP3A, upon the pharmacokinetics of olorofim .

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

F2G Biotech GmbH is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • males or females of any ethnic origin between 18 and 55 years of age
  • subjects weighing between 50 and 100 kg, with a (BMI) between 18 and 32 kg/m2.
  • subjects in good health, as determined by a medical history, physical examination, 12-lead (ECG) and clinical laboratory evaluations

Exclusion criteria

Exclusion Criteria:

  • Female subjects of .
  • Male subjects (or their partners) who are not willing to use appropriate during the study and for 3 months after end of dosing.
  • Female subjects who are pregnant or lactating.
  • Subjects who have received any prescribed systemic or topical medication within 14 days of first dose administration
  • Subjects who have used any non-prescribed systemic or topical medication within 7 days of first dose administration
  • Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of first dose administration
  • Subjects with or history of neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatry, respiratory, metabolic, endocrine, ocular haematological or other major disorders as determined by the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Cohort A

    Itraconazole DDI

    Drug: Itraconazole oral solution · Drug: Olorofim

  • Other
    Cohort B

    Rifampicin DDI

    Drug: Rifampicin Oral Capsule · Drug: Olorofim

Interventions

06

What researchers measure

Primary outcomes

  1. maximum plasma concentration (Cmax) for olorofim.

    Time frame: 16 days

  2. Area under the concentration-time curve to time of last quantifiable concentration (AUC0-tlast) for olorofim.

    Time frame: 16 days

Secondary outcomes

  1. Time to Cmax (Tmax) of olorofim

    Time frame: 16 days

  2. area under the concentration-time curve to infinity (AUC0-∞) for olorofim

    Time frame: 16 days

  3. terminal elimination half-life (t½) for olorofim

    Time frame: 16 days

  4. Number of subjects with treatment-related adverse events

    Time frame: 23 days

07

Study locations

1 site
  • Hammersmith Medicines Research
    London, NW10 7EW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Feb 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2019
First posted
Nov 21, 2019
StartActual
Nov 18, 2019
Primary completionActual
Feb 11, 2020
CompletionActual
Feb 11, 2020
Last update
Jul 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04171739
Lead sponsor
F2G Biotech GmbH
Collaborators
Hammersmith Medicines Research
Responsible party
Sponsor
First posted
Nov 21, 2019
Start date
Nov 18, 2019
Primary completion
Feb 11, 2020
Completion
Feb 11, 2020
Last update
Jul 24, 2020

Study contacts

Adeep Puri
principal investigator · Hammersmith Medicines Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Itraconazole · Rifampin · Olorofim

Start the discussion